Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al.
Ye
Yang
Y
Hu
Shen-Jiang
SJ
D001053:Apolipoproteins / Q000097:blood; D001158:Arteries / Q000187:drug effects* / Q000503:physiopathology; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications*; D003187:Compliance / Q000187:drug effects; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D000068296:Risedronic Acid; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D050071:Bone Density Conservation Agents; D014280:Triglycerides; D000068296:Risedronic Acid; D012968:Etidronic Acid